References
- Danne T, Revital N, Tadej B, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–1640. doi:10.2337/dc17-1600
- The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1C) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–983. doi:10.2337/diab.44.8.968
- Ford ES, Cowie CC, Li C, et al. Iron‑deficiency anemia, non‑iron‑deficiency anemia and HbA1C among adults in the US. J Diabetes. 2011;3(1):67–73. doi:10.1111/j.1753-0407.2010.00100.x
- Sheng X, Xiong GH, Yu PF, et al. The correlation between time in range and diabetic microvascular complications utilizing information management platform. Int J Endocrinol. 2020;2020:8879085. doi:10.1155/2020/8879085
- Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–1603. doi:10.2337/dci19-0028
- Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther. 2019;21(2):81–85. doi:10.1089/dia.2018.0310
- Ali MK, Pearson-Stuttard J, Selvin E, et al. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia. 2022;65(1):3–13. doi:10.1007/s00125-021-05585-2
- Zhu X, Zhao L, Chen J, et al. The effect of physical activity on glycemic variability in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol. 2021;12:767152. doi:10.3389/fendo.2021.767152
- Zhang XX, Kong J, Yun K. Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: a meta-analysis of observational studies. J Diabetes Res. 2020;2020:2315607. doi:10.1155/2020/2315607
- Yapanis M, James S, Craig ME, et al. Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring. J Clin Endocrinol Metab. 2022;107(6):e2221–e2236. doi:10.1210/clinem/dgac034
- Raj R, Mishra R, Jha N, et al. Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review. BMJ Open Diabetes Res Care. 2022;10(1):e002573. doi:10.1136/bmjdrc-2021-002573
- El Malahi A, Van Elsen M, Charleer S, et al. Relationship between time in range, glycemic variability, HbA1C, and complications in adults with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2022;107(2):e570–e581. doi:10.1210/clinem/dgab688
- De Ritter R, de Jong M, Vos RC, et al. Sex differences in the risk of vascular disease associated with diabetes. Biol Sex Differ. 2020;11(1):1. doi:10.1186/s13293-019-0277-z
- Lu J, Wang C, Shen Y, et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2021;44(2):549–555. doi:10.2337/dc20-1862